- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02354443
A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders (PROVIDE)
A Phase 1 Trial of a Single ProHema® CB Product as Part of Single Cord Blood Unit Transplant After Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients With Inherited Metabolic Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is an open-label trial of the safety of a single cord blood transplant using ProHema-CB following busulfan/cyclophosphamide/ATG conditioning for pediatric patients with inherited metabolic disorders.
A maximum of 12 eligible male and female subjects (1 to 18 years old, inclusive) will be enrolled and treated in the trial at approximately 1 to 3 centers within the U.S.
All subjects will be admitted to the hospital, per institutional practice and will receive a conditioning regimen, after which they will receive a HLA-matched or partially matched ProHema -CB unit on Day 0.
They will receive study follow up assessments weekly following Day 0 through Day 100 and study visit Days 180, 270, 365 and 730.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115-5450
- Boston Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have a confirmed diagnosis of an inherited metabolic disorder (IMD) and be amenable to treatment by hematopoietic cell transplantation:
- Mucopolysaccharidoses: Hurler Syndrome (MPS IH), MPS I-HS (Hurler-Scheie Syndrome), Hunter Syndrome (MPS II), Sanfilippo Syndrome (MPS III), or MPS VI (Maroteaux-Lamy syndrome) with early neurologic involvement and/or sensitization to enzyme replacement therapy (ERT); or
- Leukodystrophies: Krabbe disease (Globoid Leukodystrophy), Metachromatic Leukodystrophy (MLD), Adrenoleukodystrophy (ALD and AMN); or
- Other IMD with lysosomal storage disorder including glycoproteinoses (Alpha-Mannosidosis, Mucolipidosis II or I-Cell disease), sphingo- and other lipidoses (Sandhoff disease, Tay Sachs disease, Pelizaeus Merzbacher (PMD), Niemann-Pick disease, GM1 gangliosidosis, Wolman's disease.
- Male and female subjects aged 1 to 18 years, inclusive.
- Lack of 4 6/6 HLA matched non-carrier related UCB or 8/8 HLA A, B, C, DRß1 matched non-carrier related or 8/8 unrelated bone marrow donor; or donor not available within appropriate timeframe, as determined by the transplant physician.
- Availability of suitable primary and secondary umbilical cord blood (UCB) units.
Adequate performance status, defined as:
- Subjects ≥ 16 years: Karnofsky score ≥ 70%.
- Subjects < 16 years: Lansky score ≥ 70%.
- Cardiac: Left ventricular ejection fraction at rest must be > 40%, or shortening fraction > 26%.
Pulmonary:
- Subjects > 10 years: DLCO (diffusion capacity) > 50% of predicted (corrected for hemoglobin)
- FEV1, FVC > 50% of predicted; Note: If unable to perform pulmonary tests, then O2 saturation > 92% on room air.
- Renal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or GFR) > 70mL/min/1.73m2.
- Hepatic: Bilirubin ≤ 2.5 mg/dL (except in the case of Gilbert's syndrome, ongoing hemolytic anemia, or due to the primary IMD); and ALT, AST and Alkaline Phosphatase ≤ x 3 ULN (all elevations beyond the ULN must be secondary to the primary IMD and not a comorbid condition).
- Signed IRB approved Informed Consent Form (ICF).
Exclusion Criteria:
- Evidence of HIV infection or HIV positive serology.
- Current uncontrolled bacterial, viral or fungal infection (progression of clinical symptoms despite therapy).
- Requirement for continuous respiratory supportive therapy (e.g. ventilator). Patients on intermittent respiratory support should be discussed with the Sponsor.
- Active problems related to chronic aspiration.
- Uncontrolled seizures.
- Any active malignancy or myelodysplastic syndrome or any history of malignancy.
- Inability to give informed consent/assent or to comply with the requirements for care after allogeneic stem cell transplantation.
- Female subjects that are breastfeeding or with a positive pregnancy (HCG) test at Screening.
- Use of an investigational drug within 30 days prior to screening for the primary IMD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ProHema-CB
ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells.
Each subject will receive one administration of ProHema-CB unit transplant.
|
ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050).
The cell populations include hematopoietic stem and progenitor cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety Profile, Assessed Primarily by Neutrophil Engraftment
Time Frame: Engraftment by Day 42 following study transplant procedure
|
Engraftment by Day 42 following study transplant procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chris Storgard, MD, Fate Therapeutics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FT1050-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disorders
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
Lund UniversityCompletedMetabolic Disorders and Cognitive Decline
-
Assiut UniversityNot yet recruitingMetabolic Disorders in Children
-
Westlake UniversityCompletedPostprandial Hyperglycemia | Metabolic Disorder, GlucoseChina
-
Westlake UniversityCompletedPostprandial Hyperglycemia | Metabolic Disorder, GlucoseChina
-
Göteborg UniversityCompletedNutrition Disorders | Metabolic DisordersSweden
-
National Cheng-Kung University HospitalMinistry of Science and Technology, Taiwan; Ministry of Health and Welfare,...Recruiting
-
Novartis PharmaceuticalsWithdrawnInherited Metabolic Disorders IMD
-
University of PadovaCompletedDyslipidemias | Fatty Acid; Metabolic DisorderItaly
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
Clinical Trials on ProHema-CB Transplant
-
Fate TherapeuticsTerminatedHematologic MalignanciesUnited States
-
Fate TherapeuticsTerminatedA Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic MalignanciesHematologic MalignanciesUnited States
-
ExCellThera inc.California Institute for Regenerative Medicine (CIRM)WithdrawnSickle Cell Disease | Umbilical Cord Blood | Hematopoietic Cell ProliferationUnited States
-
ExCellThera inc.Fred Hutchinson Cancer CenterActive, not recruitingHigh Risk Hematological Malignancy | Cord Blood TransplantUnited States, Netherlands
-
University of MinnesotaRecruitingCannabis Use DisorderUnited States
-
CymaBay Therapeutics, Inc.Completed
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingDry Age-related Macular DegenerationItaly
-
Cleave Therapeutics, Inc.CompletedMyelodysplastic Syndromes | Acute Myeloid Leukemia, in RelapseUnited States, Australia
-
University of ZurichRecruitingLung Transplant Rejection | Lung Transplant Failure and RejectionSwitzerland